Lineage Cell Therapeutics, Inc. LCTX
0.99 USD -0.12 (-10.78%)
At closeNov 12, 2026, 7:57 PM EST
1.00 +0.01 +0.97%
After hours · Nov 12, 7:57 PM ET
0.9902 Day range 1.13
0.88 52-week range 1.99
- YTD
- -40.70%
- 1 year
- -48.69%
News
zacks.com Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.13 per share a year ago.
benzinga.com Lineage Acquires NeuroAirmid Therapeutics Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s DiseaseAcquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease…
businesswire.com Lineage Provides Update on ReSonance® Program for Hearing Loss CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
benzinga.com Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
defenseworld.net Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Climb 8.7% – Here’s What Happened Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) shares were up 8.7% during trading on Friday. The company traded as high as $1.04 and last traded at $1.03. Approximately…
businesswire.com Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.
marketbeat.com Lineage Cell Therapeutics Q2 Earnings Call Highlights Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease,…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.
businesswire.com Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
marketbeat.com Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
benzinga.com Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PTCOR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial DiseaseUtilizes…
businesswire.com Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel,…
businesswire.com Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…- benzinga.com Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
marketbeat.com Lineage Cell Therapeutics Q1 Earnings Call Highlights Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program…
seekingalpha.com Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
zacks.com Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
benzinga.com Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of…
businesswire.com Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
benzinga.com Earnings Scheduled For May 12, 2026 
businesswire.com Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
businesswire.com OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026 CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf”…
businesswire.com Lineage Announces Formation of Scientific Advisory Board CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel…
prnewswire.com Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
benzinga.com Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
benzinga.com HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
benzinga.com Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1 New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Lineage Cell Therapeutics Files Prospectus To Offer Up To $100M In Common Shares, Preferred Shares, Debt, And Warrants $100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more…
- benzinga.com Lineage Cell Therapeutics Files $60M ATM Share Offering Prospectus Supplement Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 (the…
- benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3 D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.
benzinga.com Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways 
benzinga.com Lineage Cell Therapeutics Q4 EPS $0.00 Beats $(0.05) Estimate, Sales $6.600M Beat $2.577M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.05) by 108.51 percent. This is a 120 percent increase over losses…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast 
benzinga.com Snowflake, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
- benzinga.com Lineage Cell Therapeutics Sold 12M Common Shares To Janus Henderson Investors At A Purchase Price Of $1.75/Share In A Block Transaction Under Its ATM Offering Program; Company Received $21M In Gross Proceeds On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under…
- benzinga.com Lineage Cell Therapeutics Q3 EPS $(0.13) Misses $(0.02) Estimate, Sales $3.681M Beat $2.300M Estimate Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.02) by 441.67 percent. This is a 550 percent decrease over…
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Lineage Cell Therapeutics Announces Launch Of A New Islet Cell Transplant Program Targeting Type 1 Diabetes Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions,…
- benzinga.com 5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know
benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.- benzinga.com Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.